Cargando…

Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Antibodies against programmed death-1 (PD-1), and its ligand, (PD-L1) have been approved recently for the treatment of small-cell lung cancer (SCLC). Although there are previous reports that addressed PD-L1 detection on tumour cells in SCLC, there is no comprehensive meta-analysis on the prevalence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Acheampong, Emmanuel, Abed, Afaf, Morici, Michael, Bowyer, Samantha, Amanuel, Benhur, Lin, Weitao, Millward, Michael, S. Gray, Elin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693331/ https://www.ncbi.nlm.nih.gov/pubmed/33142852 http://dx.doi.org/10.3390/cells9112393

Ejemplares similares

Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer
por: Acheampong, Emmanuel, et al.
Publicado: (2022)

Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
por: Acheampong, Emmanuel, et al.
Publicado: (2022)

Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression
por: Warburton, Lydia, et al.
Publicado: (2020)

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
por: Acheampong, Emmanuel, et al.
Publicado: (2019)

Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients
por: Asante, Du-Bois, et al.
Publicado: (2021)

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
por: Abed, Afaf, et al.
Publicado: (2020)

Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma
por: Klinac, Dragana, et al.
Publicado: (2014)

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2019)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
por: Dart, Sarah J., et al.
Publicado: (2021)

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
por: Calapre, Leslie, et al.
Publicado: (2019)

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2020)

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection
por: Marsavela, Gabriela, et al.
Publicado: (2020)

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies
por: Calapre, Leslie, et al.
Publicado: (2023)

Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
por: Aya-Bonilla, Carlos Alberto, et al.
Publicado: (2020)

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment
por: Gray, Elin S, et al.
Publicado: (2015)

Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma
por: McEvoy, Ashleigh C., et al.
Publicado: (2017)

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
por: Lamarca, Angela, et al.
Publicado: (2018)

Erratum to evaluation of PD-L1 expression on circulating tumour cells in small cell lung cancer
Publicado: (2022)

Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation
por: Rangamuwa, Kanishka, et al.
Publicado: (2021)

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
por: McEvoy, Ashleigh C., et al.
Publicado: (2018)

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
por: Klinac, Dragana, et al.
Publicado: (2013)

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma
por: Calapre, Leslie, et al.
Publicado: (2018)

Comparative evaluation of PD‐L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patients
por: Abdo, Mustafa, et al.
Publicado: (2023)

Tumour cell‐intrinsic CTLA4 regulates PD‐L1 expression in non‐small cell lung cancer
por: Zhang, Huijun, et al.
Publicado: (2018)

Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients
por: Asante, Du-Bois, et al.
Publicado: (2023)

Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles
por: Aya-Bonilla, Carlos, et al.
Publicado: (2019)

Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer
por: Xu, Haipeng, et al.
Publicado: (2019)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022)

Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression
por: Marsavela, Gabriela, et al.
Publicado: (2021)

Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer
por: Tang, Yin, et al.
Publicado: (2021)

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
por: Jung, Max, et al.
Publicado: (2023)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells
por: Freeman, James B, et al.
Publicado: (2012)

Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis
por: Li, Bingjia, et al.
Publicado: (2018)

Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer
por: Yoneda, Kazue, et al.
Publicado: (2019)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
por: You, Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vao8ksq828rbghdadl406dcsko